Clinical outcomes of bivalirudin for ischemic heart disease

Circulation

Volumn 100, Issue 20, 1999, Pages 2049-2053

  Kong, David F ^a   Topol, Eric J ^b   Bittl, John A ^c   White, Harvey D ^d   Théroux, Pierre ^e   Hasselblad, Vic ^a   Califf, Robert M ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c Ocala Heart and Vascular Institute   (United States)

^d GREEN LANE HOSPITAL   (New Zealand)

^e MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Bivalirudin; Hemorrhage; Meta analysis; Mortality; Myocardial infarction

Indexed keywords

CREATINE KINASE MB; HEMOGLOBIN; HEPARIN; HIRULOG; THROMBIN;

ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; META ANALYSIS; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0032738541     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.20.2049     Document Type: Article

References (28)

1. Davies MJ, Thomas AC. Plaque fissuring: the cause of acute myocardial infarction, sudden ischemic death, and crescendo angina. Br Heart J. 1985;53:363-373.
2. Cairns JA, Lewis HD, Meade TW, Sutton GC, Théroux P. Antithrombotic agents in coronary artery disease. Chest. 1995;108(suppl):380S-400S.
3. Ryan TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, Rapaport E, Riegel BJ, Russell RO, Smith EE Jr, Weaver WD. ACC/AHA Guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1996;28:1328-1428.
4. Braunwald E, Mark DB, Jones RH, Cheitlin MD, Fuster V, McCauley KM, Edwards C, Green LA, Mushlin AI, Swain JA, Smith EE III, Cowan M, Rose GC, Concannon CA, Grines CL, Brown L, Lytle BW, Goldman L, Topol EJ, Willerson JT, Brown J, Archibald N. Unstable Angina: Diagnosis and Management. Rockville, MD: Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute, US Public Health Service, US Department of Health and Human Services; March 1994. Clinical Practice Guideline No. 10, AHCPR publication No. 94-0602.
5. Maraganore JM. Preclinical and clinical studies on Hirulog: a potent and specific direct thrombin inhibitor. In: Claeson G, Scully MF, Kakkar VV, Deadman J, eds. Design of Synthetic Inhibitors of Thrombin. New York, NY: Plenum Press; 1993:227-236.
6. Topol EJ, Bonan R, Jewitt D, Sigwart U, Kakkar V, Rothman M, de Bono D, Ferguson J, Willerson JT, Strony J, Ganz P, Cohen MD, Raymond R, Fox I, Maraganore J, Adelman B. Use of a direct antithrombin, Hirulog, in place of heparin during coronary angioplasty. Circulation. 1993;87: 1622-1629.
7. Fuchs J, Cannon CP, and the TIMI 7 Investigators. Hirulog in the treatment of unstable angina: results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial. Circulation. 1995;92:727-733.
8. Lidon RM, Theroux P, Juneau M, Adelman B, Maraganore J. Initial experience with a direct antithrombin, Hirulog, in unstable angina: anticoagulant, antithrombotic, and clinical effects. Circulation. 1993;88: 1495-1501.
9. Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, Maraganore J, Deutsch E, Adelman B. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med. 1995;333:764-769.
10. Théroux P, Perez-Villa F, Waters D, Lesperance J, Shabani F, Bonan R. Randomized, double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation. 1995;91:2132-2139.
11. White HD, Aylward PE, Frey MJ, Adgey AAJ, Nair R, Hillis WS, Shalev Y, Brown MA, French JK, Collins R, Maraganore J, Adelman B, on behalf of the Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators. Randomized, double-blind comparison of Hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation. 1997;96:2155-2161.
12. Cannon CP, Maraganore JM, Loscalzo J, McAllister A, Eddings K, George D, Selwyn AP, Adelman B, Fox I, Braunwald E. Anticoagulant effects of Hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am J Cardiol. 1993;71:778-782.
13. Eddy DM, Hasselblad V. Fast*Pro Software for Meta-Analysis by the Confidence Profile Method. Boston, Mass: Academic Press, Inc; 1992.
14. Hedges LV, Olkin I. Statistical Methods for Meta-Analysis. Orlando, Fla: Academic Press; 1985.
15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
16. Popma JJ, Coller BS, Ohman EM, Bittl JA, Weitz J, Kuntz ER, Leon MB. Antithrombotic therapy in patients undergoing coronary angioplasty. Chest. 1995;108(suppl):486S-501S.
17. Kong DF, Califf RM. Post-procedure heparin: boon or burden? Am Heart J. 1998;136:183-185.
18. Handin RI, Loscalzo J. Hemostasis, thrombosis, fibrinolysis, and cardiovascular disease. In: Braunwald E, ed. Heart Disease, 4th ed. Philadelphia, Pa: WB Saunders Co; 1992:1781.
19. Bovill EG, Tracy RP, Knatterud GL, Stone PH, Nasmith J, Gore JM, Thompson BW, Tofler GH, Kleiman NS, Cannon C, Braunwald E. Hemorrhagic events during therapy with recombinant tissue plasminogen activator, heparin, and aspirin for unstable angina (Thrombolysis in Myocardial Ischemia, phase IIIB trial). Am J Cardiol. 1997;79:391-396.
20. Antman EM, for the TIMI 9B Investigators. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation. 1996;94:911-921.
21. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study. Circulation. 1997;96:769-777.
22. The GUSTO-IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med. 1996;335:775-782.
23. Parry MAA, Maraganore JM, Stone SR. Kinetic mechanism for the interaction of Hirulog with thrombin. Biochemistry. 1994;33: 14807-14814.
24. LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized controlled trials. N Engl J Med. 1997;337:536-542.
25. Thompson SG. Systematic review: why sources of heterogeneity in metaanalysis should be investigated. BMJ. 1994;309:1351-1355.
26. Pignon JP, Arrigagada R. Early stopping rules and long-term follow-up in phase III trials. Lung Cancer. 1994;10(suppl 1):S151-S159.
27. Green SJ, Fleming TR, Emerson S. Effect on overviews of early stopping rules for clinical trials. Stat Med. 1987;6:361-367.
28. Lau J, Ioannidis JPA, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127:820-826.